Archives
-
IPR-803 and the Next Era of uPAR-Targeted Translation
2026-10-06
IPR-803 is a urokinase receptor inhibitor that offers a mechanistically focused way to study uPAR–uPA biology across invasion, metastasis, angiogenesis, and tumor-stroma research. This thought-leadership analysis connects the compound’s biochemical rationale with published evidence, translational opportunities, competitive considerations, and the limitations that should shape interpretation.
-
Pheromone Signaling and Neurodegeneration in C. elegans
2026-10-05
Peng et al. show that pheromone perception during early C. elegans development can reshape neuronal signaling and increase neurodegeneration later in life. Their study links distinct chemosensory neurons to AIA interneurons, insulin-like signaling, and reduced neuronal autophagy, while also defining important limits on how broadly the findings can be applied.
-
CB-839 (Telaglenastat) in Cancer Metabolism Research
2026-10-05
CB-839, also known as Telaglenastat, is a research compound described as a selective, reversible glutaminase 1 inhibitor. Its relevance to cancer metabolism research comes from the role of GLS1 in converting glutamine-derived nitrogen and carbon into metabolites that support proliferation. A recent Cancer Letters study provides important context by showing that PRMT5 inhibition can disrupt glutamine metabolism and reduce GLS protein in MYCN-amplified neuroblastoma. However, that study did not test CB-839, so its findings support biological rationale rather than direct evidence for Telaglenastat in neuroblastoma.
-
CTOP: μ-Opioid Receptor Antagonist Research Guide
2026-10-04
CTOP is a peptide μ-opioid receptor antagonist used to examine μ-opioid receptor signaling inhibition and receptor-specific opioid effects. Yin et al. identified a brain-to-spinal pathway that regulates morphine-induced mechanical hypersensitivity and tolerance in mice, but the supplied study does not directly establish CTOP as its experimental antagonist.
-
Wnt-C59 and Wnt Signaling: Evidence and Limits
2026-10-03
Wnt-C59 is a supplier-described PORCN inhibitor used to investigate Wnt ligand secretion and Wnt-driven cancer biology. This overview compares the compound’s reported preclinical profile with a 2024 peer-reviewed study showing that lithium-enhanced exosomal Wnt10a activates the Wnt/β-catenin signaling pathway during bone regeneration. The evidence supports distinct research applications, but it does not establish clinical efficacy or justify cross-domain extrapolation.
-
G-15 as a Precision Probe of GPR30 Signaling
2026-10-02
G-15 is a G protein-coupled estrogen receptor antagonist that helps separate GPR30-driven calcium, PI3K/Akt, and proliferation responses from classical estrogen receptor activity. This article translates recent receptor-mapping research into a practical framework for designing and interpreting GPR30 assays.
-
PRMT5, Splicing, and Glutamine Metabolism in Neuroblastoma
2026-10-01
This study links PRMT5 inhibition in MYCN-amplified neuroblastoma to coordinated defects in pre-mRNA splicing, epitranscriptomic regulation, and glutamine metabolism. Its integrated cellular, molecular, metabolic, and mouse-model evidence identifies GLS regulation as a downstream vulnerability while providing a framework for biomarker-led cancer metabolism research.
-
ATG9A, PTOV1, and 14-3-3 Cancer Mechanisms
2026-10-01
The reference study identifies ATG9A and PTOV1 as previously unrecognized 14-3-3-interacting proteins and connects each interaction to a distinct regulatory mechanism. Its findings clarify how 14-3-3 signaling coordinates basal autophagy through ATG9A and oncogenic PTOV1 stability through SGK2-dependent phosphorylation.
-
IWP-2 Wnt Production Inhibitor Workflows
2026-09-30
IWP-2 enables upstream control of Porcupine-dependent Wnt secretion for pathway validation, cancer research, and epithelial cell-culture optimization. This guide translates published corneal culture work and product benchmarks into practical dosing, assay, and troubleshooting decisions.
-
Sulfaphenazole: CYP2C9 Inhibition Workflows
2026-09-30
Sulfaphenazole combines selective CYP2C9 pathway interrogation with antibacterial and vascular research utility. This guide translates its biochemical profile into practical assay workflows, dosing considerations, and troubleshooting strategies.
-
Alosetron: 5-HT3 Antagonist for Gut Research
2026-09-29
Alosetron is a selective 5-HT3 receptor antagonist used as a research probe for serotonin-linked gastrointestinal motility and visceral pain signaling. It can complement, but does not replace, studies of the CDC42–YAP–EGFR–mTOR pathway that regulates intestinal stem-cell fate.
-
Genotyping Kit for Target Alleles: Assay Design
2026-09-29
The Genotyping Kit for target alleles enables rapid PCR-ready genomic DNA preparation across insects, tissues, fishes, and cells. This article connects the K1026 workflow to mechanistic genotyping decisions inspired by research on NR1I3, CDH1, and intestinal barrier biology.
-
PRMT5–Splicing–Metabolism in MYCN Neuroblastoma
2026-09-28
The reference study shows that MYCN-amplified neuroblastoma is selectively vulnerable to PRMT5 inhibition because spliceosomal disruption propagates into epitranscriptomic control and glutamine metabolism. Its integrated use of RNA sequencing, isotope tracing, RNA methylation analysis, and mouse validation provides a framework for studying metabolically coupled vulnerabilities in high-risk neuroblastoma.
-
Measuring Glucose Uptake in Metabolic Disease Models
2026-09-28
Glucose uptake can connect molecular mechanisms to cellular function—but only when the readout is interpreted in the context of the model. This article links the Galectin-1–FIP200 findings in hepatic steatosis to practical assay design, highlighting how a WST-8 glucose uptake assay can strengthen translational studies without being mistaken for a direct measure of insulin signaling or autophagic flux.
-
Reserpine (N1867): Practical Research Workflow
2026-09-27
Reserpine (N1867) is a characterized research reagent for neurotransmitter depletion research and neuropharmacology workflows where controlled compound preparation and consistent vehicle handling are important. It is poorly soluble in water and ethanol, requires deliberate solvent selection, and is for research use only—not for diagnostic, medical, or therapeutic applications.